News & Resources
J&J to Stop Sales of Metal-on-Metal Hips
On May 16, 2013, Johnson & Johnson announced it would stop selling metal-on-metal hip replacement implants. “The decision to discontinue these products is not related to safety or efficacy, and is not a recall,” according to a company spokesperson for Johnson & Johnson’s subsidiary DePuy Orthopedics, Inc.
Alley, Clark & Greiwe included in 2013
On November 1, 2012, U.S. News Media Group and Best Lawyers® released the 2013 “Best Law Firms” rankings. We are very proud to report that for the third straight year, the law firm of Alley, Clark & Greiwe has been honored with a First-Tier ranking in the Tampa Metropolitan area in both medical malpractice and personal injury litigation.
GlaxoSmithKline to Disclose Safety Data
In a tactic admission that it has misrepresented drug trial data in the past, GlaxoSmithKline announced this week it was going to open up portions of its research to the public, which is a first for a major drug company. Researchers responded to the news with both skepticism and enthusiam.
Don Greiwe honored as Lawyer of the Year for 2013
Best Lawyers, the oldest and most respected peer-review publication in the legal profession, has named Alley, Clark & Greiwe partner Don Greiwe "Lawyer of the Year" for 2013 in Plaintiff’s Medical Malpractice Law in Tampa. After more than a quarter of a century in publication, Best Lawyers is designating Lawyers of the Year in high-profile legal specialties in large legal communities. Only a single lawyer in each specialty in each community is being honored as the Lawyer of the Year.
Johnson & Johnson’s Orthopedic Implant Woes Continue
Johnson & Johnson subsidiary DePuy Orthopaedics Inc. has recalled over 8,000 medical device units in response to the FDA finding that it sold the devices without the required approvals. The recall was disclosed on August 16, 2012, and is in response to a December letter where the FDA accused DePuy of marketing 14 various knee, hip, and ankle devices without proper approval. DePuy tried to exercise a loophole saying the devices were customized to the needs of individual patients, but the FDA disagreed. Despite receiving the warning in December, it took DePuy over 8 months to comply with the FDA request.
